February 22, 2017
Trading of Oncopeptides AB (publ) on Nasdaq Stockholm commences today
Media
February 21, 2017
GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy
February 20, 2017
Orexo Completes Bond Buyback Program
February 17, 2017
Publishing of Nexstim Plc 2016 Full Year Results
February 17, 2017
2016 ANNUAL RESULTS
February 16, 2017
Targovax ASA: Fourth quarter and full year 2016 results
February 13, 2017
Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.
February 08, 2017
Information on ReLive Trial Design and Role of its Data Safety and Monitoring Board
February 08, 2017
Oncopeptides AB (publ) announces a listing of its shares on Nasdaq Stockholm
February 06, 2017
Altimmune to Present at the BIO CEO & Investor Conference